<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01624337</url>
  </required_header>
  <id_info>
    <org_study_id>WRAIR # 1849</org_study_id>
    <secondary_id>A-17057</secondary_id>
    <nct_id>NCT01624337</nct_id>
  </id_info>
  <brief_title>Malaria Prevention Cambodia</brief_title>
  <acronym>MPC</acronym>
  <official_title>A Randomized, Double Blind, Placebo-controlled Clinical Trial of Monthly DHA-piperaquine for Malaria Prevention in Cambodia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Armed Forces Research Institute of Medical Sciences, Thailand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Centre for Parasitology, Entomology and Malaria Control, Cambodia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Cambodian Armed Forces</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Army Medical Materiel Development Activity</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Armed Forces Research Institute of Medical Sciences, Thailand</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial of monthly DHA-piperaquine for malaria prevention in health volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two arm, randomized, double-blind, placebo controlled cohort study to determine the
      protective efficacy of a monthly 2 day treatment course of Dihydroartemisinin-Piperaquine
      (DP) in adult volunteers in malaria endemic areas of Cambodia.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Medication safety concern
  </why_stopped>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Protective efficacy</measure>
    <time_frame>4 months</time_frame>
    <description>To quantify protective efficacy for the prevention of malaria infection in a setting of mixed multidrug resistant P. falciparum and P. vivax malaria, particularly in non-immune volunteers, in two treatment groups - monthly DHA-piperaquine vs. placebo.
Protective efficacy will be defined by reduction in the incidence of malaria between treatment and placebo groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac safety of piperaquine as determined by QT interval prolongation</measure>
    <time_frame>4-5 months</time_frame>
    <description>To document the effect on the electrocardiogram (EKG), particularly the QTc interval, in patients taking repeated monthly treatment courses of DHA-piperaquine.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">231</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>DHA-piperaquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DHA-piperaquine monthly 2 day treatment course</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHA-piperaquine</intervention_name>
    <description>Drug: Dihydroartemisinin piperaquine
40/320 mg tablets, 9 tablets total Arms: 2 day treatment course (4.5 tablets per day)</description>
    <arm_group_label>DHA-piperaquine</arm_group_label>
    <other_name>Duocotexcin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Volunteer 18-65 years of age

          2. Able to give informed consent

          3. Likely to reside in malaria endemic area for the duration of the study

          4. Available for follow-up for anticipated study duration, and agrees to participate for
             the duration of the study

          5. Agrees not to seek outside medical care for febrile illness, except in emergency
             situations, unless referred by study team

          6. Authorized by local commander to participate in the study if on active duty

        Exclusion Criteria:

          1. Known allergy or other contraindication to DHA, piperaquine treatment, and/or
             primaquine treatment

          2. Significant acute comorbidity requiring urgent medical intervention

          3. Positive malaria blood smear.

          4. Treatment with an antimalarial drug in the past 30 days.

          5. Pregnant or lactating female or a female of childbearing age who does not agree to use
             a highly effective method of birth control during the study

          6. Significantly abnormal EKG including a QTcF interval greater than 450ms at baseline
             (or 470ms for females) using Fridericia's correction

          7. Regular current use of known QTc prolonging medications

          8. History of sudden cardiac death in an immediate family member, or personal history of
             known symptomatic coronary artery disease or arrhythmias

          9. Judged by the investigator to be otherwise unsuitable for study participation or
             non-compliant with study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DAVID SAUNDERS, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Armed Forces Research Institute of Medical Sciences, Thailand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chanthap Lon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Armed Forces Research Institute of Medical Sciences, Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anlong Veng Referral Hospital</name>
      <address>
        <city>Anlong Veng</city>
        <state>Oddar Meancheay</state>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cambodia</country>
  </location_countries>
  <link>
    <url>http://aac.asm.org/content/58/10/6056.short</url>
    <description>Published Report of Halting</description>
  </link>
  <reference>
    <citation>Manning J, Vanachayangkul P, Lon C, Spring M, So M, Sea D, Se Y, Somethy S, Phann ST, Chann S, Sriwichai S, Buathong N, Kuntawunginn W, Mitprasat M, Siripokasupkul R, Teja-Isavadharm P, Soh E, Timmermans A, Lanteri C, Kaewkungwal J, Auayporn M, Tang D, Chour CM, Prom S, Haigney M, Cantilena L, Saunders D. Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval. Antimicrob Agents Chemother. 2014 Oct;58(10):6056-67. doi: 10.1128/AAC.02667-14. Epub 2014 Aug 4.</citation>
    <PMID>25092702</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2012</study_first_submitted>
  <study_first_submitted_qc>June 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2012</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Armed Forces Research Institute of Medical Sciences, Thailand</investigator_affiliation>
    <investigator_full_name>Philip Smith</investigator_full_name>
    <investigator_title>Chief, Department of Immunology and Medicine</investigator_title>
  </responsible_party>
  <keyword>Plasmodium falciparum</keyword>
  <keyword>Plasmodium vivax</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Piperaquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

